Not a surprise. Expect another small drop to $2.5 pps level.
Failed? Please explain yourself.
Inflammatory lesion counts is the primary endpoint in this trial. The magnitude of the difference was substantially maintained throughout the study, but differences at later measurement points were not statistically significant. Failed.
Sentiment: Strong Sell